Concept Medical has received FDA IDE approval for its MagicTouch Sirolimus Coated Balloon (SCB) for the treatment of small vessel coronary disease. This marks the third IDE approval for the MagicTouch SCB family, which already includes approvals for coronary In-Stent Restenosis (ISR) and Below-the-Knee indications. The approval paves the way for a pivotal clinical study to evaluate the safety and effectiveness of MagicTouch SCB in this challenging patient population.
Small vessel disease affects a significant portion of patients undergoing percutaneous coronary intervention (PCI), with documented prevalence rates as high as 30%. Myocardial revascularization in these small vessels presents considerable challenges, including increased rates of technical failure following coronary artery bypass graft surgery and a higher risk of restenosis following PCI, often leading to repeated interventions. Small Vessel Disease is also an independent predictor of major adverse cardiac events (MACE).
The newly granted IDE approval will enable Concept Medical to initiate a pivotal clinical study designed to establish the safety and efficacy of the MagicTouch SCB in treating small vessel coronary disease. The data generated from this study will be used to support a future pre-market approval (PMA) application in the United States.
MagicTouch SCB: A Novel Approach
MagicTouch SCB is the first Sirolimus-coated balloon globally to achieve widespread commercial adoption in Europe, Asia, and the Middle East. To date, over 100,000 patients have been treated with MagicTouch SCB in these markets. The device offers a potential alternative to drug-eluting stents (DES) and uncoated balloons, which are currently the primary options available to physicians in the US for treating coronary artery disease (CAD).
Currently, there are no FDA-approved drug-coated balloons for the treatment of CAD in the USA. MagicTouch SCB has been evaluated in multiple clinical trials, including the EASTBOURNE Registry (2123 patients), NANOLUTE, and ongoing trials such as TRANSFORM 1, TRANSFORM 2, GINGER, TITAN, and Hybrid Bifurcation DEB. These studies have contributed to establishing the safety profile of Sirolimus in the treatment of coronary artery disease.
Expert Perspective
Dr. Martin Leon, MD, Founder and Chairman Emeritus of the Cardiovascular Research Foundation, will lead the upcoming IDE Trials. He emphasized the significance of this milestone, stating, "The FDA-approval to initiate the MAGICAL-SV Clinical trial using the MagicTouch sirolimus-covered balloon with novel coating technology represents a landmark event in our decades-long quest to find an optimal therapy to manage patients with small vessel coronary obstructive disease. Our US clinical investigators are thrilled and anxious to begin enrolment in close collaboration with the Cardiovascular Research Foundation and Concept Medical."
